Parts of this work were presented at the Joint The Royal Society of Medicine/British Association of Otorhinolaryngologists-Head and Neck Surgeons (RSM/ENT) United Kingdom Annual Meeting, London, September 2007, and at the 112th American Academy of Otolaryngology-Head and Neck Surgery Foundation Annual Meeting, Chicago, Illinois, September 2008.
Serum IL10 and circulating CD4+CD25high regulatory T cell numbers as predictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma†
Article first published online: 19 JUL 2010
Copyright © 2010 Wiley Periodicals, Inc.
Head & Neck
Volume 33, Issue 3, pages 415–423, March 2011
How to Cite
Alhamarneh, O., Agada, F., Madden, L., Stafford, N. and Greenman, J. (2011), Serum IL10 and circulating CD4+CD25high regulatory T cell numbers as predictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma. Head Neck, 33: 415–423. doi: 10.1002/hed.21464
- Issue published online: 11 FEB 2011
- Article first published online: 19 JUL 2010
- Manuscript Accepted: 30 MAR 2010
- regulatory T cells;
- antitumor immunity;
Patients with head and neck squamous cell carcinoma (HNSCC) commonly have an imbalance in T helper (Th)1/Th2-type cytokines and elevated levels of CD4+CD25high regulatory T cells (Treg). Here, we investigated the association of circulating interleukin (IL)10, IL12, and Treg-cells with clinical outcome in patients with HNSCC.
Serum cytokine levels were determined by enzyme-linked immunosorbent assay (ELISA) in patients' pretreatment (n = 107) and 4 to 6 weeks posttreatment (n = 43), and in nontumor controls (n = 40). Treg-cell levels were determined by flow cytometry.
IL10 detectability was significantly higher in patients than controls (p = .001). Pretreatment IL10 levels in all anatomical subsites, except the oral cavity, were significantly elevated in stages III/IV, N+ patients, and in T3/4-tumors (p = .005, .037, and .001, respectively). The detectability of IL10 significantly correlated with poorer survival after a maximum follow-up of 36 months. Treg-cell levels did not correlate with any clinical parameters.
IL10 is a potential independent factor in predicting a poor clinical outcome in newly presenting tumors of laryngeal and pharyngeal origin. The role of circulating Treg-cells as predictors of clinical outcome requires further investigation. © 2010 Wiley Periodicals, Inc. Head Neck, 2010